This Analyst Slashes PT On Lyft By 68%, Plus Telsey Advisory Group Predicts $125 For Nike

9/26/22 8:28:36 AM ET

Containers/Packaging

Industrials

Specialty Insurers

Finance

Get the next $BALL alert in real time by email

UBS cut Lyft, Inc. (NASDAQ:LYFT) price target from $50 to $16. Lyft shares fell 3.7% to $13.47 in pre-market trading.
Telsey Advisory Group cut NIKE, Inc. (NYSE:NKE) price target from $130 to $125. NIKE shares fell 0.9% to $96.12 in pre-market trading.
Jefferies cut Golden Ocean Group Limited (NASDAQ:GOGL) price target from $14 to $10. Golden Ocean Group shares fell 7.1% to $7.69 in pre-market trading.
UBS lowered the price target on Immunovant, Inc. (NASDAQ:IMVT) from $7 to $5. Immunovant shares fell 2.9% to $4.74 in pre-market trading.
HC Wainwright & Co. cut price target for Spero Therapeutics, Inc. (NASDAQ:SPRO) from $7 to $6. Spero Therapeutics shares rose 2% to $2.01 in pre-market trading.
JonesTrading lowered the price target on RE/MAX Holdings, Inc. (NYSE:RMAX) from $34 to $28. RE/MAX Holdings shares fell 2.6% to $17.96 in pre-market trading.
Stephens & Co. cut the price target for Fidelity National Financial, Inc. (NYSE:FNF) from $52 to $49. Fidelity National Financial fell 4.1% to $35.01 in pre-market trading.
Raymond James cut the price target on Matador Resources Company (NYSE:MTDR) from $70 to $60. Matador Resources fell 0.8% to $49.02 in pre-market trading.
Citigroup reduced the price target on Ball Corporation (NYSE:BALL) from $64 to $54. Ball shares rose 1.8% to $50.00 in pre-market trading.
Morgan Stanley raised the price target on ProFrac Holding Corp. (NYSE:PFHC) from $28 to $30. ProFrac Holding shares fell 4.5% to close at $16.01 on Friday.

Don’t forget to check out our premarket coverage here .

Check out this: Fear & Greed Index Moves To Extreme Fear Zone After Dow Settles Below 30,000

Get the next $BALL alert in real time by email

Crush Q1 2026 with the Best AI Superconnector

Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

AI-Powered Inbox

Context-aware email replies

Strategic Decision Support

Get Started with Standout.work

Recent Analyst Ratings for
$BALL
$FNF
$GOGL
$IMVT

Company	Date	Price Target	Rating	Analyst
Matador Resources Company $MTDR	1/27/2026	$47.00	Overweight → Equal Weight	Wells Fargo
Nike Inc. $NKE	1/8/2026		Hold	Deutsche Bank
Nike Inc. $NKE	1/8/2026		Buy → Hold	Needham
Ball Corporation $BALL	1/8/2026	$63.00	Overweight → Equal-Weight	Morgan Stanley
Immunovant Inc. $IMVT	1/6/2026	$50.00	Peer Perform → Outperform	Wolfe Research
Ball Corporation $BALL	1/6/2026	$60.00	Underweight → Overweight	Wells Fargo
Ball Corporation $BALL	1/6/2026	$67.00	Neutral → Buy	Citigroup
Lyft Inc. $LYFT	12/19/2025	$16.00	Neutral → Underperform	Wedbush

More analyst ratings

$BALL
$FNF
$GOGL
$IMVT
Press Releases

Fastest customizable press release news feed in the world

Lyft Reports Record Q4 and Full-Year 2025 Results

Delivered accelerated Q4 Gross Bookings growth year over year; on track with 2027 targets Announces new $1 billion share repurchase program Lyft, Inc. (NASDAQ:LYFT) today announced record financial results for the fourth quarter and full year ended December 31, 2025. "2025 was an incredible year in Lyft's comeback story. Through customer obsession, we're transforming from your local, "out-to-dinner" rideshare app to a global, hybrid transportation platform," said CEO David Risher. "As we look ahead, we are entering a transformational phase for Lyft - 2026 will be the year of the AV with deployments in the U.S. and overseas." "We delivered record financial performance in 2025 across

2/10/26 4:05:00 PM ET

Real Estate

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

2/6/26 7:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Fidelity National Financial Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

JACKSONVILLE, Fla., Feb. 5, 2026 /PRNewswire/ -- Fidelity National Financial, Inc. (NYSE:FNF) (FNF), a leading provider of title insurance and transaction services to the real estate and mortgage industries and a leading provider of insurance solutions serving retail annuity and life customers and institutional clients through its majority-owned, publicly traded subsidiary F&G Annuities & Life, Inc. (NYSE:FG) (F&G), will release fourth quarter and full year 2025 earnings after the close of regular market trading on Thursday, February 19, 2026. A webcast and conference call to discuss the results will follow at 11:00 a.m. Eastern Time on Friday, February 20, 2026. Additional information abou

2/5/26 4:15:00 PM ET

Life Insurance

Finance

Specialty Insurers

$BALL
$FNF
$GOGL
$IMVT
Financials

Live finance-specific insights

Immunovant Provides Corporate Updates and Reports Financial Results for the Third Quarter Ended December 31, 2025

IMVT-1402 potentially registrational trial in difficult-to-treat rheumatoid arthritis (D2T RA) fully enrolled, with topline data expected in the second half of calendar year 2026; topline data from the proof-of-concept trial in cutaneous lupus erythematosus (CLE) expected in the second half of calendar year 2026IMVT-1402 development is progressing with potentially registrational studies in Graves' disease (GD), myasthenia gravis (MG), chronic inflammatory demyelinating polyneuropathy (CIDP) and Sjögren's disease (SjD) remaining on trackUnderwritten financing with key institutional investors and Roivant generated approximately $550 million in gross proceeds, extending Immunovant's cash runway

2/6/26 7:00:00 AM ET

Biotechnology: Biological Products (No Diagnostic Substances)

Health Care

Fidelity National Financial Announces Fourth Quarter and Full Year 2025 Earnings Release and Conference Call

JACKSONVILLE, Fla., Feb. 5, 2026 /PRNewswire/ -- Fidelity National Financial, Inc. (NYSE:FNF) (FNF), a leading provider of title insurance and transaction services to the real estate and mortgage industries and a leading provider of insurance solutions serving retail annuity and life customers and institutional clients through its majority-owned, publicly traded subsidiary F&G Annuities & Life, Inc. (NYSE:FG) (F&G), will release fourth quarter and full year 2025 earnings after the close of regular market trading on Thursday, February 19, 2026. A webcast and conference call to discuss the results will follow at 11:00 a.m. Eastern Time on Friday, February 20, 2026. Additional information abou

2/5/26 4:15:00 PM ET

Life Insurance

Finance

Specialty Insurers

Ball Reports Strong Fourth Quarter and Full-Year 2025 Results

Highlights Full-year and fourth quarter U.S. GAAP diluted earnings per share of $3.30 and 75 cents, respectivelyFull-year and fourth quarter comparable diluted earnings per share of $3.57 and 91 cents, respectivelyFull-year and fourth quarter global aluminum packaging shipments up 4.1% and 6.0%, respectivelyReturned $1.54 billion to shareholders via share repurchases and dividends in 2025Generated record adjusted free cash flow of $956 million in 2025Completed acquisition of majority stake in European beverage can manufacturer BenepackIn 2026, expect comparable diluted earnings per share growth of 10-plus percent and free cash flow greater than $900 millionFocused on advancing sustainable al

2/3/26 6:00:00 AM ET

Containers/Packaging

Industrials